$NVAX

US stock indexes closed higher on Wednesday, with Moderna's 177% surge driving healthcare gains. Merck rose 12.6%, and the S&P 500 healthcare sector gained 3.5%. Bond yields eased after Treasury announced support for longer-dated bonds. Dow, S&P 500, and Nasdaq saw modest gains. Target, Lowe's, and Estee Lauder also reported notable moves.

Stocks rose as Treasury yields eased after the Treasury Department announced increased bond buybacks. Merck (MRK) and Moderna (MRNA) surged on positive cancer drug data. Target (TGT) gained after reporting better-than-expected earnings. Marvell (MRVL) rose on a deal with Google (GOOGL).

U.S. indexes rebounded as bond yields eased, with Moderna's shares more than doubling after positive trial results. Merck rose 11.2%, and healthcare stocks gained. Tech stocks were flat, with Broadcom down 4% and Marvell up 9.8%. The Dow, S&P 500, and Nasdaq all rose. Target and Estee Lauder also reported positive updates.

U.S. stock indexes closed modestly higher on Wednesday, driven by easing bond yields and a surge in Moderna shares. Moderna's stock rose nearly 177% after positive trial results for its cancer therapy, boosting healthcare stocks. The S&P 500 healthcare sector gained 3.5%, its biggest one-day gain since April 2025. The Dow, S&P 500, and Nasdaq Composite all posted gains, while the Fed minutes showed concerns about inflation and potential rate hikes.

U.S. stock indexes closed higher on Wednesday as bond yields eased, boosting risk appetite. Moderna's shares surged after positive trial results for its cancer therapy, driving gains in the healthcare sector. The S&P 500, Nasdaq, and Dow Jones all posted modest gains. Merck and healthcare peers also saw gains, while tech stocks dipped.

Novavax (NVAX) shares rose 6.9% after positive trial results from Moderna and Merck boosted vaccine sector sentiment. The companies' cancer vaccine reduced melanoma recurrence in trials. Novavax's shares are volatile, with a 22.7% YTD gain but still 21.8% below its 52-week high. The company reported Q4 revenue of $147.1M, up 67% YoY, and EPS of $0.11, beating expectations.

Shares of BioNTech (BNTX), Moderna (MRVI), Regeneron (RGEN), and Novavax (NVAX) rose 20%, 25%, 6%, and 6% respectively after a Moderna-Merck cancer vaccine trial succeeded. Analysts expect benefits for Merck and suppliers like Repligen, Danaher, Thermo Fisher, and Maravai. TEM stock gained 2% YTD, with 8/16 analysts rating it 'Buy' or higher, and a 27% potential upside from its last close.

Novavax (NVAX) shares rose 5.17% to $8.34 on Wednesday, following a positive Phase 3 trial result from Merck and Moderna for a personalized cancer vaccine. The success boosted the biotech sector, with the SPDR S&P Biotech ETF (XBI) up over 4%. Novavax's adjuvant platform may benefit from increased interest in advanced vaccine technologies.

Novavax (NVAX) shares rose 5.17% to $8.34 on Wednesday, following a positive Phase 3 trial result from Merck and Moderna for a personalized cancer vaccine. The success sparked a broader rally in biotech stocks, benefiting Novavax due to its adjuvant platform, which enhances immune responses and has potential applications in oncology and respiratory diseases.

Moderna (MRNA) and Merck (MRK) reported that their mRNA-based cancer vaccine met primary goals in a Phase 3 trial for melanoma, sending MRNA shares up 156% and MRK up 10%. The vaccine, combined with Merck's Keytruda, showed significant reduction in melanoma recurrence and spread. This is the first successful Phase 3 result for an mRNA cancer therapy, according to the companies. Analysts remain mixed on the stocks' outlook.